Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Restructuring: 2020-2023

Historic Cash from Restructuring for Lifecore Biomedical (LFCR) over the last 2 years, with Feb 2023 value amounting to $2.6 million.

  • Lifecore Biomedical's Cash from Restructuring fell 51.35% to $2.6 million in Q1 2023 from the same period last year, while for Feb 2023 it was $34.1 million, marking a year-over-year increase of 172.99%. This contributed to the annual value of $1.4 million for FY2024, which is 119.06% up from last year.
  • Lifecore Biomedical's Cash from Restructuring amounted to $2.6 million in Q1 2023, which was up 355.77% from $563,000 recorded in Q4 2022.
  • In the past 5 years, Lifecore Biomedical's Cash from Restructuring ranged from a high of $30.0 million in Q2 2022 and a low of $563,000 during Q4 2022.
  • In the last 3 years, Lifecore Biomedical's Cash from Restructuring had a median value of $2.1 million in 2021 and averaged $5.4 million.
  • Its Cash from Restructuring has fluctuated over the past 5 years, first crashed by 83.08% in 2021, then spiked by 447.24% in 2022.
  • Over the past 4 years, Lifecore Biomedical's Cash from Restructuring (Quarterly) stood at $1.1 million in 2020, then tumbled by 42.95% to $627,000 in 2021, then dropped by 10.21% to $563,000 in 2022, then plummeted by 51.35% to $2.6 million in 2023.
  • Its Cash from Restructuring was $2.6 million in Q1 2023, compared to $563,000 in Q4 2022 and $1.0 million in Q3 2022.